|
Recent developments in myelodysplastic syndromes
|
Sep 2014
|
Blood
|
myelodysplastic syndromes (MDS)
|
|
Origins of myelodysplastic syndromes after aplastic anemia
|
Sep 2017
|
Blood
|
aplastic anemia
|
|
Recent developments in myelodysplastic syndromes
|
Sep 2014
|
Blood
|
myelodysplastic syndromes (MDS)
|
|
Reduced ribosomal RNA expression and increased ribosomal DNA promoter methylation in CD34+ cells of patients with myelodysplastic syndromes
|
Oct 2012
|
Blood
|
myelodysplastic syndromes (MDS)
|
|
BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders.
|
Sep 2013
|
Blood
|
myelodysplastic syndromes (MDS)
|
|
SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes
|
Jul 2012
|
Blood
|
myelodysplastic syndromes (MDS)
|
|
How we treat lower risk myelodysplastic syndromes.
|
Apr 2013
|
Blood
|
myelodysplastic syndromes (MDS)
|
|
Newly revised 2023 MDS response criteria
|
Apr 2023
|
Blood
|
myelodysplastic syndromes (MDS)
|
|
"Moderate" dose cyclophosphamide for severe aplastic anemia has significant toxicity and does not prevent relapse and clonal evolution.
|
Sep 2014
|
Blood
|
aplastic anemia
|
|
Initial experience with L-leucine therapy in myelodysplastic syndromes with associated chromosome 5q deletion.
|
May 2013
|
Blood
|
myelodysplastic syndromes (MDS)
|
